M4MM
Definium Achieves Second Positive Phase 3 for GAD
NEW YORK – Definium Therapeutics Inc. released topline data from its second pivotal Phase 3 trial (Panorama study) of DT120 in generalized anxiety disorder (GAD), adding to earlier positive findings in the same indication and ...
High Tide Reports Q3 2026 Financial Results
CALGARY – High Tide Inc. posted revenue of $198.8 million for the three months ended July 31, 2026, a 33% increase from the same period last year and the fifth consecutive quarterly record. Gross profit ...
Curaleaf Escalates Aurora Fight, Asks Alberta Regulator to Freeze Share Sales
STAMFORD – Curaleaf Holdings Inc. submitted a formal application to the Alberta Securities Commission (ASC), seeking to halt Aurora Cannabis's at-the-market share issuance program while Curaleaf's offer to acquire all outstanding Aurora shares remains outstanding. ...
Dutch Cannabis Supply Pilot Delivers Lower Prices and a Fuller Shelf
AMSTERDAM – A report published by the Trimbos Institute, RAND Europe, and Breuer&Intraval compared ten municipalities where coffeeshops sell exclusively licensed-grown Сannabis against ten operating under the country's traditional tolerance policy. The program launched April ...
Cannara Secures Upgraded $80M Credit Line
MONTREAL – Cannara Biotech Inc. announced that its operating subsidiary has entered into an amended and restated syndicated credit agreement with Bank of Montreal (BMO) and The Toronto-Dominion Bank (TD), establishing $80 million in committed ...
Virginia Unveils Draft Rules for Adult-Use Cannabis Market
RICHMOND – The Virginia Cannabis Control Authority (CCA) released an 80-plus-page draft regulatory framework for the state's forthcoming adult-use market – the first detailed set of proposed rules since the General Assembly authorized commercial sales ...
Metrc Rolls Out Compliance Events for New York Cannabis Operators
NEW YORK – Track-and-trace provider Metrc announced a pair of statewide User Exchange events in New York, one in New York City on September 14 and another in Syracuse on September 16, designed to help ...
Definium Achieves Second Positive Phase 3 for GAD
NEW YORK – Definium Therapeutics Inc. released topline data from its second pivotal Phase 3 trial (Panorama study) of DT120 in generalized anxiety disorder (GAD), adding to earlier positive findings in the same indication and ...
High Tide Reports Q3 2026 Financial Results
CALGARY – High Tide Inc. posted revenue of $198.8 million for the three months ended July 31, 2026, a 33% increase from the same period last year and the fifth consecutive quarterly record. Gross profit ...
Curaleaf Escalates Aurora Fight, Asks Alberta Regulator to Freeze Share Sales
STAMFORD – Curaleaf Holdings Inc. submitted a formal application to the Alberta Securities Commission (ASC), seeking to halt Aurora Cannabis's at-the-market share issuance program while Curaleaf's offer to acquire all outstanding Aurora shares remains outstanding. ...
Portugal Medical Cannabis Outpaces 2025 Export Run Rate
LISBON – Portugal's medicines regulator, Infarmed, has confirmed that the country exported 66,305 kilograms of medical Cannabis between January and June 2026, equivalent to more than 80% of everything it shipped in all of 2025. ...
UMiami Hands Over Its 1994 Ibogaine Research to Washington
LOS ANGELES – The University of Miami has donated its original 1994 investigational new drug (IND) application for ibogaine to the federal government, giving Washington direct operational authority over the foundational FDA authorization that made ...
CRB Monitor and NCS Analytics Partner to Bridge the Cannabis Compliance Data Gap
DENVER – Two of the industry's most data-intensive platforms that have long operated on parallel tracks in the Cannabis compliance space announced a formal partnership, combining regulatory licensing records with real-time operational analytics into a ...
Decibel Reports Q2 2026 Financial Results
CALGARY – Decibel Cannabis Co. Inc. reported second-quarter net revenue of $35.6 million for the period ended June 30, 2026, the best three-month result in the company's history. A licensed Canadian Cannabis producer simultaneously raised ...
Organigram Pulls Sanity Group Into a Single Global Structure
TORONTO – Organigram Global Inc. did not wait out the calendar. Roughly four months after the April 2026 closing of its acquisition of Sanity Group GmbH, the Canadian Cannabis producer announced an accelerated integration of ...
Aurora Takes Ownership of UK Patient Supply Chain with Birmingham Acquisitions
EDMONTON – Aurora Cannabis Inc. has acquired two licensed UK pharmaceutical entities, consolidating vertical control of its distribution network in one of Europe's most active medical Cannabis markets. Through a wholly owned subsidiary, Aurora announced ...
Texas’s Dazed Inc Claims Expansion and Buyback Strategy
AUSTIN – Dazed Inc., formerly MedX Holdings, Inc., released a corporate update covering retail expansion, Q2 2026 financial results, a planned stock buyback, and product distribution. The company announced a signed franchise agreement for a ...
Analysis: The DEA Is Now Fighting to Move Cannabis to Schedule III
WASHINGTON, D.C.,- For more than 50 years, the Drug Enforcement Administration has helped enforce federal Cannabis prohibition. This week, the DEA formally argued that Cannabis no longer belongs in Schedule I. In its final written ...
Under Delisting Pressure, IM Cannabis Approves Reverse Stock Split
TORONTO – IM Cannabis Corp. (IMCC), a medical Cannabis company operating in Israel and Germany, announced that its board has approved a one-for-thirty share consolidation, effective August 27, with September 15 as the outside date. ...
Johnson & Johnson Signs On to Lead Delix’s $85M Series C
NEW BRUNSWICK – Johnson & Johnson has agreed to lead a Series C financing for Delix Therapeutics, the biotech developing non-hallucinogenic drugs designed to promote neuroplasticity in patients with serious psychiatric conditions. The round is ...
Analysis: Wall Street Quietly Tests the Water In Cannabis
NEW YORK- For years, institutional investors have largely remained outside the publicly traded Cannabis market. Federal illegality, regulatory uncertainty, limited access to major exchanges and disappointing stock performance have kept most major investment firms on ...
Earnings Season: Cannabis Operators Deliver a Different Kind of Q2 2026
LOS ANGELES – The Cannabis industry wraps up its second-quarter earnings, and the aggregate picture carries a theme that would have been harder to locate a few years ago. Operators are making money. Profitability, not ...
Yale Budget Lab Outlines Multibillion Dollar Future for Federal Cannabis
NEW HAVEN – The fiscal argument for federal Cannabis legalization now has an academic backbone. Yale University's Budget Lab released a comprehensive revenue analysis mapping out what a federal excise tax on Cannabis could realistically ...
Definium Delivers Positive Phase 3 Data for LSD Candidate in GAD
NEW YORK – Definium Therapeutics Inc. has released topline results from the first of two Phase 3 studies testing its LSD-based candidate DT120 in adults with generalized anxiety disorder (GAD). The findings add to earlier ...
Week in Review: Cannabis & Psychedelics Industry Highlights
LOS ANGELES – A hostile takeover bid, a Senate hemp vote that reset the enforcement calendar without solving anything, a state tax repeal with constitutional teeth, a dense Q2 earnings wave, and two landmark banking ...
